Article

Encouraging Results from Imbruvica in CLL and Small Lymphocytic Lymphoma

Improved survival without disease progression prompted independent reviewers to unblind the study comparing Imbruvica against a placebo, in combination with bendamustine and rituximab.

An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

Pharmacyclics, which recently agreed to be acquired by AbbVie Inc for about $21 billion, said Imbruvica showed a statistically significant improvement in survival without disease progression, the study's main goal.

Imbruvica, which is co-marketed by Pharmacyclics and J&J, is already approved for four cancer indications in the United States.

Link to the Reuters report:

http://reut.rs/1Gijzad

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Nini Wu, MD, Navista
Eileen Peng, PharmD, sitting for a video interview
Related Content
AJMC
June 11th 2025

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

Brigham Walker, PhD Lalan Wilfong, MD Nicholas Robert, MD Alexander Siebert, PhD J. Russell Hoverman, MD, PhD
A private oncology shared savings plan reduced colon cancer treatment costs. Results varied by tumor, with none in breast cancer and mixed effects in lung cancer.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com
June 6th 2025

Novel Biomarkers May Inform Prognosis in SCLC

AJMC Contributor
The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell lung cancer (SCLC).
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
young adult cancer | Image credit: Roswell Park Cancer Center
June 6th 2025

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

Mary Caffrey
Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50. Obesity is among the factors linked to rising rates of cancer in young adults.
FDA headquarters | Image Credit: - Tada Images- stock.adobe.com
June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick
In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo